Introducing Workiva Carbon
Workiva Inc. (NYSE: WK), a global leader in assured integrated reporting, today announced the launch of Workiva Carbon. The new offering advances its ESG and Sustainability Platform for organizations to support the requirements of global climate regulations, including the Corporate Sustainability Reporting Directive (CSRD), SEC’s climate disclosure rules, and California’s Climate Corporate Data Accountability Act (SB 253) and Climate-Related Financial Risk Act (SB 261). Workiva Carbon simplifies the management of net zero targets that thousands of organizations have established voluntarily to meet international guidelines, respond to stakeholder demands for transparency, and better compete in the global economy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240618250028/en/
With Workiva Carbon, companies can:
- Measure: Collect real-time data from their ERP platforms, accounting systems, and utility providers, and track greenhouse gas (GHG) emissions across facilities and locations using thousands of externally validated emissions factors that cover 240+ countries and territories. This data enables companies to automatically calculate carbon emissions across scope 1, 2, and 3.
- Manage: Create supplier engagement surveys with easy-to-fill forms that capture and connect critical data to reports and dashboards, enabling them to set science-based targets and reduction pathways, assess ESG risk, and take steps to decarbonize the supply chain.
- Collaborate: Gather, share, and link the same set of trusted data to deliverables across business functions–including sustainability, accounting, finance, audit, risk, legal, and more–without the risks associated with manual edits, multiple versions, downloads of disparate spreadsheets, or last-minute changes.
- Report: Automatically align emissions data to voluntary and mandated frameworks created within the Workiva platform and deliver consistent disclosures for regulators, investors, and other audit-ready stakeholders, thanks to full data lineage and history, attached evidence, and granular permissions.
“The launch of Workiva Carbon enhances Workiva’s established and leading ESG platform, positioning us to help businesses advance their sustainability efforts,” said Julie Iskow, president and chief executive officer of Workiva. “Now our customers can streamline Greenhouse Gas (GHG) emissions tracking, set science-based targets, and meet stakeholder demands amidst the changing investor and regulatory landscape. Bringing these carbon capabilities into our platform highlights our unwavering commitment to providing our customers a comprehensive solution for Financial reporting, ESG, and GRC.”
Workiva Carbon combines technology and expertise from our recent Sustain.Life acquisition with the power of the Workiva platform. Sustain.Life has been helping companies with their carbon accounting and emissions reporting across industries worldwide since its inception. We are delighted to welcome the Sustain.Life team of experts with their industry-leading technology to Workiva. Together, we can make an even greater impact and accelerate our mission to power transparent reporting for a better world. Click here to learn more.
About Workiva
Workiva Inc. (NYSE: WK) is on a mission to power transparent reporting for a better world. We build and deliver the world’s leading cloud platform for assured, integrated reporting to meet stakeholder demands for action, transparency, and disclosure of financial and non-financial data. Workiva offers the only unified SaaS platform that brings customers’ financial reporting, Environmental, Social, and Governance (ESG), and Governance, Risk, and Compliance (GRC) together in a controlled, secure, audit-ready platform. Our platform simplifies the most complex reporting and disclosure challenges by streamlining processes, connecting data and teams, and ensuring consistency. Learn more at workiva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240618250028/en/
Contacts
Investor Contact:
Mike Rost
investor@workiva.com
Media Contact:
Rotha Brauntz
press@workiva.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM31.8.2025 12:15:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the 12-month follow-up of the ongoing open-label extension (OLE) period of HELIOS-B were presented during an oral session at the European Society of Cardiology (ESC) Congress 2025 held in Madrid, Spain. These data reflect outcomes of treatment through up to 48 months, including the initial double-blind period of 33-36 months, and highlight the ongoing clinical benefit of vutrisiran, which causes rapid knockdown of the disease-causing transthyretin (TTR) protein, including a 37% risk reduction in the composite endpoint of all-cause mortality (ACM) or first cardiovascular (CV) event in the overall population (p<0.001) and a 42% risk reduction in th
WETEX Opens Broad Investment Horizons for International Companies31.8.2025 09:30:00 EEST | Press release
Under the directives of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the patronage of HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy, Dubai Electricity and Water Authority (DEWA) will organise the 27th edition of the Water, Energy, Technology and Environment Exhibition (WETEX) from 30 September to 2 October 2025 at the Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250830023664/en/ WETEX opens broad investment horizons for international companies (Photo: AETOSWire) WETEX embodies the UAE's pioneering position in clean and renewable energy and sustainability. It also supports Dubai's ambitious vision of a sustainable economy. The exhibition covers multiple areas including water, energy, smart cities, green mobility, artificial intelligence and digital transformation. “WETEX reflects the UAE's unwa
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 19:00:00 EEST | Press release
Daiichi Sankyo Europe is pleased to announce the initiation of the development of new oral triple combination tablets in Europe of bempedoic acid, ezetimibe, and different doses of a statin (atorvastatin or rosuvastatin), with the potential to lower low-density lipoprotein cholesterol (LDL-C) levels.9 It is well known that combination therapies reduce the pill burden for patients, potentially enhancing treatment adherence and facilitating treatment with a goal of improving cardiovascular outcomes.9,10 “As bempedoic acid and ezetimibe are already approved as a single-dose therapy, the development of an oral triple combination tablet with different doses of a statin, can make it easier for physicians to tailor treatment to the individual needs of each patient,” says Dr. Stefan Seyfried, Vice President and Head Medical Affairs Specialty Medicines, Daiichi Sankyo Europe. “This approach exemplifies our dedication to our motto: ‘we care for every heartbeat’.” “The management of dyslipidaemia
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 17:30:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from the comprehensive KARDIA Phase 2 program, including KARDIA-3 results presented today as a late-breaking abstract at the European Society of Cardiology (ESC) Congress in Madrid, Spain. Zilebesiran is an investigational subcutaneously administered RNAi therapeutic which, in the KARDIA Phase 2 program, has shown reductions in blood pressure by targeting liver-expressed angiotensinogen (AGT), the most upstream precursor in the Renin-Angiotensin-Aldosterone System (RAAS), which plays a key role in blood pressure regulation and impacts cardiovascular and renal health. KARDIA-3, the third Phase 2 study in the KARDIA program, evaluated the efficacy and safety of zilebesiran in patients with
BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and durable responses and offer the first BCL2 inhibitor for patients with R/R MCL, if approved,” said Lai Wang, PhD, Global Head of R&D, BeOne Medicines. “These data add to the remarkable progress we’ve seen over the past five years in treating B-cel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom